Many cancers are treated with chemotherapies that affect DNA repair, such as platinum chemotherapy, and some patients derive significant benefit from these agents. However, the underlying genomic features that drive selective response to these treatments is incompletely characterized. Dr. Van Allen aims to blend precision cancer medicine principles with DNA repair treatments and enhance cancer care. He will do so by studying the genomics of response to existing and emerging DNA repair therapies in preclinical models as well as patients across different tumor types.
Damon Runyon Researchers
Meet Our Scientists
Eliezer M. Van Allen, MD
Project title: "Dissecting response to conventional and emerging DNA damage and repair therapies"
Institution: Dana-Farber Cancer Institute
Award Program: Clinical Investigator
Sponsor(s) / Mentor(s): Geoffrey I. Shapiro, MD, PhD
Cancer Type: All Cancers
Research Area: Computational Biology
